23:08 , Aug 10, 2018 |  BioCentury  |  Finance

Takeda gets Ambys-tious

After a two-year search, Takeda Pharmaceutical Co. Ltd.’s equity investment and option deal with newco Ambys Medicines finally gets the ball rolling on the pharma’s goal of building a liver franchise within its core area...
18:45 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

ASIT reports additional Phase III data for gp-ASIT+ in rhinitis

ASIT biotech S.A. (Euronext:ASIT) reported additional data from the double-blind, international Phase III BTT009 trial in 554 patients with grass pollen-induced allergic rhinitis with or without controlled asthma showing that once-weekly subcutaneous gp-ASIT+ for a...
05:13 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

gp-ASIT+: Ph III data

A double-blind, European Phase III trial in 554 patients with moderate to severe seasonal grass pollen-induced allergic rhinitis showed that subcutaneous gp-ASIT+ improved clinical symptoms and reduced medication use by 15-21% vs. placebo. ASIT biotech...
19:35 , Dec 2, 2016 |  BC Week In Review  |  Clinical News

Subcutaneous hdm-ASIT+: Completed Ph IIa enrollment

ASIT completed enrollment of 37 patients in the double-blind, placebo-controlled, German Phase IIa hdmASIT-001 trial evaluating subcutaneous hdm-ASIT+. ASIT biotech S.A. (Euronext:ASIT), Brussels, Belgium  Product: Subcutaneous hdm-ASIT+   Business: Inflammation  Molecular target: NA  Description: Natural...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Subcutaneous hdm-ASIT+: Phase IIa started

ASIT began a double-blind, placebo-controlled, German Phase IIa trial to evaluate subcutaneous hdm-ASIT+ in about 45 allergic patients. ASIT biotech S.A. (Euronext:ASIT), Brussels, Belgium   Product: Subcutaneous hdm-ASIT+   Business: Inflammation   Molecular target: NA...